Patents by Inventor Toshimitsu ENDO

Toshimitsu ENDO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUND HAVING LYSOPHOSPHATIDIC ACID RECEPTOR AGONIST ACTIVITY AND PHARMACEUTICAL USE THEREOF
    Publication number: 20230014137
    Abstract: A pharmaceutical containing a compound having an agonist activity for LPA3 as an active ingredient, wherein the compound is of formula (IY): wherein all symbols represent the same meaning as described in the specification, and which is useful as a preventive and/or therapeutic agent for, e.g., essential thrombocythemia or reactive thrombocytosis.
    Type: Application
    Filed: November 27, 2020
    Publication date: January 19, 2023
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Yuzo IWAKI, Toshimitsu ENDO, Kensuke KUSUMI
  • COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY
    Publication number: 20220055986
    Abstract: A compound represented by the general formula (V) wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
    Type: Application
    Filed: November 8, 2021
    Publication date: February 24, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshihide WATANABE, Kensuke KUSUMI, Satomi IMAIDE, Toshimitsu ENDO, Takaki KOMIYA, Naomi TSUBURAYA
  • Compounds having S1P5 receptor agonistic activity
    Patent number: 11198672
    Abstract: A compound represented by the general formula (V) wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: December 14, 2021
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshihide Watanabe, Kensuke Kusumi, Satomi Imaide, Toshimitsu Endo, Takaki Komiya, Naomi Tsuburaya
  • COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY
    Publication number: 20210087141
    Abstract: A compound represented by the general formula (V) wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
    Type: Application
    Filed: February 21, 2019
    Publication date: March 25, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshihide WATANABE, Kensuke KUSUMI, Satomi IMAIDE, Toshimitsu ENDO, Takaki KOMIYA, Naomi TSUBURAYA